Research Paper Volume 14, Issue 17 pp 6887—6904

Figure 5. (I) Effect of developmental ACR exposure on immunolocalization of ovarian GDF-9 localization in AF1 treated groups compared to control CF1. Normal control CF1 females (A–C). Immunolocalization of GDF-9 protein in AF1 females treated with the dose of 2.5 mg/kg (D–F), 10 mg/kg (G–I), and 20 mg/kg (J–L). (II) CYP19 relative intensity in 4-week-old AF1 females compared with control CF1. (III) Effect of developmental ACR exposure on immunolocalization of ovarian GDF-9 localization in AF2 treated groups compared to control CF2. The normal control CF2 females (A–C), immunolocalization of GDF-9 protein in AF2 females treated with the dose of 2.5 mg/kg (D–F), 10 mg/kg (G–I)), and 20 mg/kg (J–L). (IV) The GDF-9 relative intensity in 4-week-old AF2 females compared with control (CF2). Sections of the ovary was performed by immunofluorescence using specific GDF-9 antibody stained with FITC (green), and cell nuclei were stained with Hoechst (blue). Scale bar = 20 μm.